The Manufacturers Life Insurance Company Has $1.26 Million Stock Position in Xenon Pharmaceuticals Inc. $XENE

The Manufacturers Life Insurance Company lessened its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 33.5% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,684 shares of the biopharmaceutical company’s stock after selling 10,938 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Xenon Pharmaceuticals were worth $1,261,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Bank of New York Mellon Corp grew its position in Xenon Pharmaceuticals by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 396,138 shares of the biopharmaceutical company’s stock worth $23,035,000 after acquiring an additional 8,980 shares during the last quarter. Peregrine Capital Management LLC bought a new position in Xenon Pharmaceuticals in the fourth quarter valued at about $7,837,000. Siren L.L.C. raised its position in Xenon Pharmaceuticals by 62.2% in the first quarter. Siren L.L.C. now owns 1,318,564 shares of the biopharmaceutical company’s stock valued at $76,674,000 after purchasing an additional 505,803 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Xenon Pharmaceuticals by 13.8% during the fourth quarter. Jennison Associates LLC now owns 1,292,055 shares of the biopharmaceutical company’s stock valued at $57,910,000 after purchasing an additional 156,820 shares in the last quarter. Finally, NEXTBio Capital Management LP acquired a new stake in shares of Xenon Pharmaceuticals during the fourth quarter valued at about $8,234,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Price Performance

NASDAQ XENE opened at $63.22 on Wednesday. The business has a 50 day simple moving average of $60.67 and a 200 day simple moving average of $54.62. Xenon Pharmaceuticals Inc. has a one year low of $35.10 and a one year high of $72.66. The stock has a market capitalization of $6.11 billion, a P/E ratio of -13.34 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.05. During the same period in the prior year, the firm earned ($1.07) EPS. Equities analysts expect that Xenon Pharmaceuticals Inc. will post -4.91 earnings per share for the current year.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the sale, the director directly owned 24,896 shares in the company, valued at approximately $1,322,973.44. This trade represents a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director owned 1,455 shares in the company, valued at $77,318.70. This represents a 44.99% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.91% of the stock is owned by insiders.

Xenon Pharmaceuticals News Summary

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $74 price target, above the stock’s recent trading level near $63. The firm raised its EPS forecasts for 2026 through 2030, including a narrower expected loss of $4.48 per share in fiscal 2026, $4.88 in 2027, $3.89 in 2028, $2.23 in 2029 and $0.18 in 2030. The revisions suggest the analyst expects Xenon’s losses to narrow faster than previously projected. HC Wainwright estimates for Xenon Pharmaceuticals
• Neutral Sentiment: Reported short-interest data showed zero shares sold short as of August 11, compared with zero shares in the prior reporting period, producing a zero-day days-to-cover ratio. Because the report also displays an invalid “NaN” percentage change, it offers no meaningful indication of changing bearish positioning or potential short-covering support.
• Negative Sentiment: Xenon is still expected to report substantial losses, with consensus fiscal-year EPS of negative $4.92 and HC Wainwright forecasting additional quarterly losses through 2027. As a development-stage biopharmaceutical company, XENE remains dependent on clinical and commercial execution, while the provided updates contain no new drug-development or regulatory catalyst. Equities Analysts Set Expectations for XENE Q1 Earnings

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. upped their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. HC Wainwright reiterated a “buy” rating and set a $74.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday. Royal Bank Of Canada reduced their target price on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a report on Friday. Wells Fargo & Company restated an “overweight” rating and issued a $69.00 price target on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Finally, Needham & Company LLC dropped their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Xenon Pharmaceuticals has a consensus rating of “Buy” and an average price target of $77.13.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.